Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by Sunbelt Securities Inc.

Sunbelt Securities Inc. lessened its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 20.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 110,890 shares of the biotechnology company’s stock after selling 29,135 shares during the period. Sunbelt Securities Inc. owned approximately 0.08% of Aurinia Pharmaceuticals worth $1,017,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Blue Trust Inc. grew its holdings in Aurinia Pharmaceuticals by 3,041.4% during the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 6,174 shares during the period. Atria Wealth Solutions Inc. acquired a new stake in Aurinia Pharmaceuticals in the 4th quarter valued at about $135,000. Arrowstreet Capital Limited Partnership bought a new position in shares of Aurinia Pharmaceuticals during the 4th quarter valued at about $9,662,000. Price T Rowe Associates Inc. MD grew its stake in shares of Aurinia Pharmaceuticals by 19.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 52,098 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 8,350 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Aurinia Pharmaceuticals by 6.9% in the 4th quarter. Vanguard Group Inc. now owns 1,729,948 shares of the biotechnology company’s stock worth $15,535,000 after purchasing an additional 112,113 shares in the last quarter. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Down 2.3%

Shares of Aurinia Pharmaceuticals stock opened at $8.08 on Friday. Aurinia Pharmaceuticals Inc. has a 12-month low of $5.11 and a 12-month high of $10.67. The firm has a market capitalization of $1.09 billion, a PE ratio of -53.86 and a beta of 1.16. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The stock’s fifty day moving average is $8.02 and its 200-day moving average is $8.27.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.08. Aurinia Pharmaceuticals had a negative return on equity of 4.41% and a negative net margin of 10.23%. The firm had revenue of $62.47 million for the quarter, compared to the consensus estimate of $61.06 million. Equities analysts anticipate that Aurinia Pharmaceuticals Inc. will post 0.11 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 27th.

Insider Activity at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, insider Greg Keenan sold 12,239 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $97,912.00. Following the sale, the insider now directly owns 161,789 shares of the company’s stock, valued at $1,294,312. The trade was a 7.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Joseph M. Miller sold 61,859 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $494,872.00. Following the completion of the sale, the chief financial officer now directly owns 633,515 shares of the company’s stock, valued at approximately $5,068,120. This trade represents a 8.90% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 343,898 shares of company stock worth $2,753,094. 4.30% of the stock is owned by corporate insiders.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.